コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 MGUS is a premalignant disorder frequently encountered i
2 MGUS is considered an obligate precursor to several lymp
3 MGUS patients frequently mount a humoral and cellular im
4 MGUS patients had an 8.01-fold (5.40-11.43) increased ri
5 MGUS was identified in 694 (3.2 percent) of these person
6 MGUS was present in 100.0% (87.2%-100.0%), 98.3% (90.8%-
7 g multiple myeloma (SMM) or MGUS (11 SMM, 17 MGUS) who had normal karyotype, 11 cases of hyperdiploid
8 n-based data from Sweden, we identified 4458 MGUS patients, 17505 population-based controls, and firs
9 ne mineral density (vBMD) measurements in 50 MGUS patients (20 females, 30 males; mean +/- SEM age, 7
10 omography imaging of the distal radius in 50 MGUS patients and 100 age-, gender-, and body mass index
11 drome (OFD1) had response in 6 of 29 (20.6%) MGUS patients but 0 of 11 newly diagnosed MM patients.
14 ct was significantly increased to 1.80 after MGUS, 1.70 after MM, 1.85 after WM and 2.31 after AL amy
18 Associations between pesticide exposures and MGUS prevalence were assessed by logistic regression mod
22 r the increased risk of multiple myeloma and MGUS in blacks is related to socioeconomic status, genet
31 vation that a low M-protein concentration at MGUS diagnosis was associated with poorer MM survival ma
32 , low M-protein concentration (<0.5 g/dL) at MGUS diagnosis was associated with poorer MM survival (H
35 n active multiple myeloma clone and a benign MGUS clone, and thus provides a unique model to assess t
47 e disorders for light-chain and conventional MGUS and assessed incidence of renal disorders in patien
48 g the light-chain equivalent of conventional MGUS and posing a risk of progression to light-chain mul
50 n=22) and patients with stringently defined MGUS/smoldering MM (n=24) and symptomatic MM (n=351) (P<
55 sed cohort, previously assembled to estimate MGUS prevalence, of 21,463 residents of Olmsted County,
56 n epidemiology and risk factors for familial MGUS and myeloma, the risk of lymphoproliferative disord
61 ranslated into a 2.4-fold increased risk for MGUS in Ranch Hand veterans than comparison veterans aft
63 9 years) of similar socioeconomic status for MGUS; the aim of the study was to assess MGUS risk in re
65 study conducted in 2013 to 2014, testing for MGUS in serum specimens collected and stored in 2002 by
68 expression is increased on plasma cells from MGUS patients compared with normal donors, whereas MM pa
69 sion and profiled CD138(+) plasma cells from MGUS, SMM, and MM specimens; human myeloma cell lines; a
70 M, 44 with MGUS (24+20), and 16 with MM from MGUS created 2 major cluster branches, one containing 82
72 way are associated with the progression from MGUS to MM and raise the possibility that anti-MICA mono
73 e mechanisms underlying the progression from MGUS to MM are incompletely understood but include the s
76 uding IgM cases, 0/14), and immunoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P <
78 an 50 years (n = 555), 38 were found to have MGUS, yielding a prevalence of 6.8% (95% CI, 5.0%-9.3%).
84 gammopathy multiple myeloma with IgG or IgA MGUS clones were subsequently identified from the three
85 k MGUS patients (>/= 1.5 g/dL and/or non-IgG MGUS) were more likely to be optimally followed (81% vs
86 in 97 of 104 (93%) WM and 13 of 24 (54%) IgM MGUS patients and was either absent or rarely expressed
87 P as a widely present mutation in WM and IgM MGUS patients using highly sensitive and specific AS-PCR
88 iation between peripheral neuropathy and IgM MGUS with characteristic clinical, electrophysiology and
89 8q11-18q23] progressively increased from IgM MGUS and smoldering WM vs symptomatic WM (18% vs 20% and
92 clonal B cells that, albeit benign (ie, IgM MGUS and smoldering WM), already harbor the phenotypic a
94 Risk was confined to IgG/IgA, while no IgM MGUS patients developed AML/MDS; patients with monoclona
97 cells from newly diagnosed patients with IgM MGUS (n = 22), smoldering (n = 16), and symptomatic WM (
98 1q and 4q when patients with WM and with IgM MGUS were both considered affected; nonparametric linkag
99 for AML/MDS following IgG/IgA (but not IgM) MGUS, and the highest risk associated with M-protein con
101 gammopathy of undetermined significance (IgM-MGUS), 84 with splenic marginal zone lymphoma (SMZL), an
104 100%) patients with WM, 36/77 (47%) with IgM-MGUS, 5/84 (6%) with SMZL, and 3/52 (4%) with B-CLPD.
108 P < .01) were all significantly decreased in MGUS patients, suggestive of impaired bone formation.
110 GE proteins is stronger and more frequent in MGUS compared with myeloma with a predominantly CD45RA(-
115 t evidence of altered bone microstructure in MGUS and suggest that cytokines elevated in osteolytic m
116 plasmocytes from MM patients but neither in MGUS patients nor in healthy individuals, suggesting tha
118 e confirmed T-cell responses against OFD1 in MGUS and observed down-regulation of GLI1/PTCH1 and p-be
125 mong residents of Olmsted County, Minnesota, MGUS was found in 3.2 percent of persons 50 years of age
129 Among first-degree relatives of a nationwide MGUS cohort, we found elevated risks of MGUS, MM, LPL/WM
132 and glaucoma and tested the associations of MGUS, MM, WM and AL amyloidosis with subsequent eye dise
134 are few reports about the clinical course of MGUS or risk profile in long-term immunosuppressed patie
138 credited to hematologists, the discovery of MGUS is most often incidental and made by nonhematologis
139 To better define the skeletal effects of MGUS, we performed aBMD and high-resolution peripheral q
147 than MM patients without prior knowledge of MGUS (median survival, 2.1 years), although MM patients
149 Patients with MM with prior knowledge of MGUS had better MM survival, suggesting that earlier tre
151 Patients with MM with prior knowledge of MGUS had significantly (HR, 0.86; 95% CI, 0.77-0.96; P <
152 Among MM patients with prior knowledge of MGUS, low M-protein concentration (<0.5 g/dL) at MGUS di
154 s for improving individualized management of MGUS and SMM patients, as well as the potential for deve
160 ay contribute to the increased prevalence of MGUS among relatives of probands with MGUS, MM, and othe
161 determined longitudinally the prevalence of MGUS and characterized patterns of monoclonal immunoglob
162 ry techniques to ascertain the prevalence of MGUS in a large population in a well-defined geographic
163 how that there is an increased prevalence of MGUS in blood relatives of persons with lymphoproliferat
166 om Minnesota, the age-adjusted prevalence of MGUS was 1.9-fold (95% CI, 1.3- to 2.7-fold) higher amon
169 ed risk of MGUS in first-degree relatives of MGUS or MM patients implies shared environment and/or ge
170 red with relatives of controls, relatives of MGUS patients had increased risk of MGUS (relative risk
172 tives of MGUS patients had increased risk of MGUS (relative risk [RR] = 2.8; 1.4-5.6), multiple myelo
173 Analyses of populations at increased risk of MGUS also suggest the possible existence of a polyclonal
174 s (n = 58387) with the aim to assess risk of MGUS and lymphoproliferative malignancies among first-de
176 etection methods, there was a higher risk of MGUS in relatives (age-adjusted risk ratio [RR], 2.6; 95
178 (95% CI, 1.1- to 5.3-fold) increased risk of MGUS prevalence was observed among users of the chlorina
179 erans have a significantly increased risk of MGUS, supporting an association between Agent Orange exp
181 wide MGUS cohort, we found elevated risks of MGUS, MM, LPL/WM, and CLL, supporting a role for germlin
182 DNA expression library to screen the sera of MGUS patients to identify tumor-associated antigens.
188 To examine the impact of these 7 SNPs on MGUS, we analyzed two case-control series totaling 492 c
189 Emerging evidence from molecular studies on MGUS and SMM, involving cytogenetics, gene-expression pr
190 hieved with anti-multiple myeloma therapy on MGUS (which we defined as M2) and multiple myeloma (M1)
191 ividuals from all backgrounds; however, only MGUS, MM, and WM patients who were HSP90-SUMO1 carriers
193 ts with smoldering multiple myeloma (SMM) or MGUS (11 SMM, 17 MGUS) who had normal karyotype, 11 case
196 tion of earlier stages, which we term as pre-MGUS Analyses of populations at increased risk of MGUS a
198 as NPCs transition to MM, create a high-risk MGUS gene signature, and subgroup International Staging
204 ts with MM, 128 (6.6%) developed a secondary MGUS, at a median of 12 months from the diagnosis of MM.
205 erior in MM patients who developed secondary MGUS compared with the rest of the cohort (73 vs 38 mont
207 time of onset and the duration of secondary MGUS, as well as failure to resolve spontaneously, had a
211 nal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) comprise heterogeneous d
212 nal gammopathy of undetermined significance (MGUS) and multiple myeloma for expression of cancer-test
213 nal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), suggesting
215 nal gammopathy of undetermined significance (MGUS) are at increased fracture risk, and we have previo
217 nal gammopathy of undetermined significance (MGUS) has been observed in case reports and in smaller s
218 nal gammopathy of undetermined significance (MGUS) have increased cortical bone porosity and reduced
219 nal gammopathy of undetermined significance (MGUS) is a common disorder of aging and a precursor lesi
220 nal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell proliferative disord
221 nal gammopathy of undetermined significance (MGUS) is an asymptomatic plasma cell proliferative disor
222 nal gammopathy of undetermined significance (MGUS) is an asymptomatic premalignant plasma cell disord
223 nal gammopathy of undetermined significance (MGUS) is associated with a long-term risk of progression
224 nal gammopathy of undetermined significance (MGUS) is defined by expression of heavy-chain immunoglob
225 nal gammopathy of undetermined significance (MGUS) is increased in first-degree relatives of multiple
226 nal gammopathy of undetermined significance (MGUS) is present in approximately 2% of individuals age
227 nal gammopathy of undetermined significance (MGUS) is the most commonly found monoclonal gammopathy a
229 nal gammopathy of undetermined significance (MGUS) is, in many ways, a unique hematologic entity.
234 nal gammopathy of undetermined significance (MGUS) referred to our hospital for acute painless drop o
236 nal gammopathy of undetermined significance (MGUS) represents a precursor lesion to myeloma (MM).
238 nal gammopathy of undetermined significance (MGUS) to lymphoplasmacellular and myeloid malignancies i
239 nal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is driven by defects in d
240 nal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is thought to be associat
241 nal gammopathy of undetermined significance (MGUS) to multiple myeloma are unclear but may include th
242 nal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), is one of t
243 nal gammopathy of undetermined significance (MGUS), a premalignant plasma-cell disorder, among person
244 nal gammopathy of undetermined significance (MGUS), and five cases of prostate cancer in two generati
245 nal gammopathy of undetermined significance (MGUS), asymptomatic myeloma (AMM), and multiple myeloma
246 nal gammopathy of undetermined significance (MGUS), followed up to 30 years (median, 10 years), we es
248 nal gammopathy of undetermined significance (MGUS), multiple myeloma (MM), Waldenstrom macroglobuline
249 l gammopathies of undetermined significance (MGUS), multiple myelomas (MM), and Waldenstrom's macrogl
250 nal gammopathy of undetermined significance (MGUS), which is usually only treated by a form of anti-m
257 nal gammopathy of undetermined significance (MGUS); however, to our knowledge, no studies have uncove
258 nal gammopathy of undetermined significance (MGUS; n = 14), smoldering multiple myeloma (SMM; n = 31)
259 nal gammopathy of undetermined significance (MGUS; n=17), smoldering multiple myeloma (SMM; n=40), an
260 noclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) are asymptom
263 nal gammopathy of undetermined significance [MGUS], presentation myeloma, and plasma cell leukemia).
274 ture risk, and we have previously shown that MGUS patients have altered trabecular bone microarchitec
279 DLI response; 2 of 12 (17%) patients in the MGUS pretreatment control population also had detectable
280 cluster branches, one containing 82% of the MGUS patients and the other containing 28% of the MM pat
283 l failure, anemia, and bone lesions, whereas MGUS and smoldering myeloma are diagnosed based on labor
284 d epigenetic alterations that affect whether MGUS plasma cell clones are responsive to anti-multiple
286 clustering of 351 patients with MM, 44 with MGUS (24+20), and 16 with MM from MGUS created 2 major c
287 discuss the potential harms associated with MGUS diagnosis, a topic that is rarely, if ever, broache
289 of individuals with MGUS is consistent with MGUS being a marker of inherited genetic susceptibility
290 yeloma (MM) in relatives of individuals with MGUS is consistent with MGUS being a marker of inherited
291 lure, and mortality between KT patients with MGUS and a matched cohort of KT recipients without MGUS.
292 ncies among blood-relatives of patients with MGUS and MM, and discusses future directions for researc
293 dividualized risk profiles for patients with MGUS and SMM represents an ongoing challenge that has to
294 he current standard of care of patients with MGUS and SMM, the use of risk models, including flow cyt
296 ing personalized management of patients with MGUS or smoldering myeloma, as well as the potential for
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。